Paul E. Freiman, Director at NovaBay Pharmaceuticals, Inc. (NBY), bought 3,000 shares at $0.84 ($3K) on 2011-09-12, disclosed to the SEC on 2011-09-13.
Open-market purchase of $3k NBY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |